Mvasi 25mg/ml Infusionsl sung,1ST x 400mg(bevacizumab)

Reference priceKRW ₩233,280.00Original source price: INR 14,400.00. Converted estimates are available by currency selection.

Brand	Mvasi
Manufacturer	Amgen GmbH
Prescription required	Yes

Description

Mvasi 25mg/ml Infusionsl sung,1ST x 400mg(bevacizumab) is a medicine catalog record in the MediPriceHub database. Active ingredient: bevacizumab. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Amgen GmbH. Therapeutic category: Medicine Library > Oncology Medicines > Kidney Cancer Drugs. Pack information: 25 / 400 1. Origin country or market: Germany. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

LYTENAVA is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).

How to Use

Use bevacizumab under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: bevacizumab. Pack size: 25 / 400 1. Pack unit: bottle. Manufacturer: Amgen GmbH. Origin country: Germany. Source category: Medicine Library > Oncology Medicines > Kidney Cancer Drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Injectable and infusion products may also cause administration-site pain, swelling, infection, infusion reactions, or hypersensitivity. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.

이 정보는 참고용입니다. 의약품 사용 전 의료 전문가와 상담하세요.